Search results
Results from the WOW.Com Content Network
Gen-Probe was a company based in San Diego, in California, specializing in clinical diagnostics, blood screening, transplantation products and research products.. The company's molecular diagnostics products were used for diagnosis of infectious diseases, blood screening, analyzing blood transfusions for immune response, testing coagulation pathways, and organ transplantation viability.
Transcription-mediated amplification (TMA) is an isothermal (performed at constant temperature), single-tube nucleic acid amplification system utilizing two enzymes, RNA polymerase and reverse transcriptase.
In the decade of the 2000s, the two most common commercially available tests were the amplified mycobacterium tuberculosis direct test (MTD, Gen-Probe) and Amplicor (Roche Diagnostics). In 2007, a systematic review of NAAT by the NHS Health Technology Assessment Programme concluded that "NAAT test accuracy to be far superior when applied to ...
What: Shares of diagnostic test company Gen-Probe. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they ...
Gen-Probe (NAS: GPRO) reported earnings on Feb. 13. Here are the numbers you need to know. The 10-second takeawayFor the quarter ended Dec. 31 (Q4), Gen-Probe met expectations on revenues and ...
For premium support please call: 800-290-4726 more ways to reach us
n/a Ensembl ENSG00000225937 n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) Chr 9: 76.69 – 76.86 Mb n/a PubMed search n/a Wikidata View/Edit Human Prostate cancer antigen 3 (PCA3, also referred to as DD3) is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer ...
(Reuters) -The U.S. House of Representatives committee on China has asked the FBI and the intelligence community for a briefing on GenScript Biotechnology Co and three subsidiaries to determine if ...